Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
NCT ID: NCT06236438
Last Updated: 2026-01-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2/PHASE3
167 participants
INTERVENTIONAL
2024-04-10
2031-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide.
Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In cohort 3, participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed . In cohort 4, participants will receive IV Infused pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. Stage 2: In arm 1, participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In arm 2, participants will receive IV Infused placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. The estimated study duration is 55 months.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
NCT06946797
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
NCT06561386
Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of Chemotherapy
NCT07024862
A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy
NCT02864251
An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)
NCT02477826
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Stage 1 (Cohort 1): Livmoniplimab Dose A
Participants will receive livmoniplimab (dose A)+ budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
Livmoniplimab
Intravenously (IV) Infusion
Budigalimab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Stage 1 (Cohort 2): Livmoniplimab Dose B
Participants will receive livmoniplimab (dose B) + budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
Livmoniplimab
Intravenously (IV) Infusion
Budigalimab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Stage 1 (Cohort 3): Budigalimab
Participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed.
Budigalimab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Stage 1 (Cohort 4): Pembrolizumab
Participants will receive pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
Pembrolizumab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Stage 2 (Arm 1): Livmoniplimab (Dose Optimized)
Participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed.
Livmoniplimab
Intravenously (IV) Infusion
Budigalimab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Stage 2 (Arm 2): Placebo
Participants will receive placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed.
Pembrolizumab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Livmoniplimab
Intravenously (IV) Infusion
Budigalimab
IV Infusion
Pembrolizumab
IV Infusion
Pemetrexed
IV Infusion
Cisplatin
IV Infusion
Carboplatin
IV Injection
Carboplatin
IV Infusion
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Must have at least 1 measurable lesion per response evaluation criteria in solid tumors (RECIST) v1.1 as determined by the local site Investigator/radiology assessment.
* Life expectancy of at least 3 months and adequate organ function.
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AbbVie
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
ABBVIE INC.
Role: STUDY_DIRECTOR
AbbVie
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Moores Cancer Center /ID# 267782
La Jolla, California, United States
Memorial Hospital West /ID# 262221
Pembroke Pines, Florida, United States
Bond Clinic /ID# 262611
Winter Haven, Florida, United States
University Cancer & Blood Cent /ID# 261824
Athens, Georgia, United States
The University of Chicago Medical Center /ID# 262259
Chicago, Illinois, United States
University of Kansas Medical Center /ID# 263196
Westwood, Kansas, United States
Baptist Health Lexington /ID# 261823
Lexington, Kentucky, United States
Cancer & Hematology Centers of Western Michigan - East /ID# 261826
Grand Rapids, Michigan, United States
Washington University-School of Medicine /ID# 262759
St Louis, Missouri, United States
Stony Brook Cancer Center /ID# 261954
Stony Brook, New York, United States
Cone Health Cancer Center /ID# 262583
Greensboro, North Carolina, United States
Oncology Hematology Care, Inc - Blue Ash /ID# 262733
Cincinnati, Ohio, United States
Guthrie Robert Packer Hospital /ID# 262758
Sayre, Pennsylvania, United States
Renovatio clinical /ID# 262000
El Paso, Texas, United States
Houston Methodist Hospital /ID# 262722
Houston, Texas, United States
Texas Oncology - Plano East /ID# 264356
Plano, Texas, United States
Texas Oncology - San Antonio Medical Center - Research Drive /ID# 264311
San Antonio, Texas, United States
Renovatio Clinical /ID# 261999
The Woodlands, Texas, United States
Vista Oncology - East Olympia /ID# 262303
Olympia, Washington, United States
Canberra Hospital /ID# 261891
Garran, Australian Capital Territory, Australia
Nepean Hospital /ID# 262157
Kingswood, New South Wales, Australia
Westmead Hospital /ID# 261894
Westmead, New South Wales, Australia
Universitair Ziekenhuis Antwerpen /ID# 261270
Edegem, Antwerpen, Belgium
Cliniques Universitaires UCL Saint-Luc /ID# 261267
Brussels, Brussels Capital, Belgium
Hospital La Louviere Site Jolimont - Helora /ID# 261269
La Louvière, Hainaut, Belgium
Groupe Sante CHC - Clinique du MontLegia /ID# 262338
Liège, Liege, Belgium
AZ Maria Middelares /ID# 262313
Ghent, , Belgium
UCL Namur University Hospital, Site Sainte-Elisabeth /ID# 262557
Namur, , Belgium
Oncored /Id# 261801
Vitacura, Region Metropolitana Santiago, Chile
Centro de Investigacion y Desarrollo Oncologico /ID# 261800
Temuco, Región de la Araucanía, Chile
Sociedad Cem-Cancer Spa /Id# 262316
Viña del Mar, Región de Valparaíso, Chile
Fundacion Arturo Lopez Perez /ID# 261700
Providencia, Santiago Metropolitan, Chile
Hospital Clinico Universidad De Los Andes /ID# 262665
Santiago, , Chile
APHM - Hopital Nord /ID# 261129
Marseille, Bouches-du-Rhone, France
CHU Grenoble - Hopital Michallon /ID# 261131
La Tronche, Isere, France
Institut Curie /ID# 261127
Paris, Paris, France
Hospices Civils de Lyon (HCL) - Hopital Louis Pradel /ID# 261644
Bron, Rhone, France
Centre Hosp Intercommunal de Creteil /ID# 261130
Créteil, Val-de-Marne, France
Shaare Zedek Medical Center /ID# 262432
Jerusalem, Jerusalem, Israel
Rambam Health Care Campus /ID# 262431
Haifa, , Israel
National Cancer Center Hospital East /ID# 261923
Kashiwa-shi, Chiba, Japan
Saitama Prefectural Cancer Center /ID# 262703
Kitaadachi-gun, Saitama, Japan
National Cancer Center Hospital /ID# 261925
Chuo-ku, Tokyo, Japan
Ziekenhuis St. Jansdal /ID# 261193
Harderwijk, Gelderland, Netherlands
Zuyderland Medisch Centrum /ID# 261190
Heerlen, Limburg, Netherlands
Isala /ID# 262458
Zwolle, Overijssel, Netherlands
Pan American Center for Oncology Trials /ID# 269666
Rio Piedras, , Puerto Rico
Complejo Hospitalario Universitario de Santiago (CHUS) /ID# 262723
Santiago de Compostela, A Coruna, Spain
Institut Català d'Oncologia (ICO) - L'Hospitalet /ID# 262118
L'Hospitalet de Llobregat, Barcelona, Spain
UOMi Cancer Center - Clinica Tres Torres /ID# 262116
Barcelona, , Spain
Hospital Universitario Vall de Hebron /ID# 262113
Barcelona, , Spain
Hospital General Universitario Gregorio Maranon /ID# 262114
Madrid, , Spain
Hospital Universitario 12 de Octubre /ID# 262112
Madrid, , Spain
Hospital Clinico Universitario de Valencia /ID# 262115
Valencia, , Spain
National Cheng Kung University Hospital /ID# 262016
Tainan, , Taiwan
Mackay Memorial Hospital /ID# 262534
Taipei, , Taiwan
Taipei Medical University Hospital /ID# 262020
Taipei, , Taiwan
Linkou Chang Gung Memorial Hospital /ID# 262535
Taoyuan, , Taiwan
Gazi University Medical Faculty /ID# 261786
Ankara, , Turkey (Türkiye)
Ankara City Hospital /ID# 261785
Ankara, , Turkey (Türkiye)
Dr. Suat Seren Gogus Has /ID# 261789
Izmir, , Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2023-505773-32-00
Identifier Type: OTHER
Identifier Source: secondary_id
M23-721
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.